PDCD1 and neoplasm: Despite a few reports showing that TFR cells are significantly increased in cancer patients compared to healthy controls [57, 58], and a recent study showing that TIL TFR cells curtail anti-PD-1 therapeutic efficacy [59], their mechanisms of action in the tumor remain unclear.